FLOW: Semaglutide for Diabetes and Kidney Disease

Here, I provide a brief summary of the FLOW study on semaglutide’s effects in patients with type 2 diabetes and chronic kidney disease. This study highlights the benefits of semaglutide in reducing the risks of kidney failure, cardiovascular events, and death. We will delve into the key findings and results published in the New England Journal of Medicine in May 2024.